Posts

Posted on

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment

NORWOOD, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, today announced the dosing of the first patient in the  Phase 1 portion of the clinical study of CRB-601 for the treatment of patients with advanced solid tumors (NCT06603844). CRB-601 is a monoclonal antibody targeting latent TGFβ activation-by blocking the integrin αVβ8. Pre-clinical data has demonstrated that CRB-601 overcomes tumor immune exclusion and enhances the activity of immune checkpoint inhibitors in vivo.

“CRB-601 offers an intriguing upstream approach to modulating TGFβ signaling and this dose escalation study could yield valuable insights along with the potential to see the immune system being mobilized and the prospect of tumors responding.” said Dr. Dominic Smethurst, MA, MRCP, Chief Medical Officer of Corbus.”

“Dosing CRB-601 in a clinical trial marks an important milestone, bringing us closer to understanding its potential in the clinic and paving the way for advancements in an exciting corner of immunotherapy,” said Dr. Jeffrey M. Clarke, MD., Associate Professor of Medicine, Associate Director of Thoracic Oncology Clinical Research Program, Duke Cancer Institute, Raleigh, NC. and a principal investigator in the CRB-601 study.

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Facebook, LinkedIn and X.  

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


INVESTOR CONTACT:

Sean Moran

Chief Financial Officer

Corbus Pharmaceuticals
[email protected]

Bruce Mackle

Managing Director

LifeSci Advisors, LLC
[email protected]



Posted on

Iron Mountain announces the election of June Yee Felix to the Board of Directors

Iron Mountain announces the election of June Yee Felix to the Board of Directors

June Yee Felix joins the Board of Directors effective January 1, 2025

PORTSMOUTH, N.H.–(BUSINESS WIRE)–
Iron Mountain Incorporated (NYSE: IRM), a global leader in information management services, today announced that it has elected June Yee Felix to the Board of Directors, effective January 1, 2025.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209488444/en/

June Yee Felix (Photo: Business Wire)

June Yee Felix (Photo: Business Wire)

Ms. Felix is an accomplished global executive with three decades of extensive leadership experience in the financial services, fintech and technology sectors. From 2018 to 2023, Ms. Felix was Group CEO of IG Group plc, a global fintech company, having served on its board as a non-executive director from 2015 to 2018. Ms. Felix was a regional president at Verifone from 2014 to 2018, and also held senior leadership positions at Citibank, IBM and Chase Manhattan Bank during her career.

Since 2020, Ms. Felix has served as a non-executive director of RELX PLC, a global provider of information-based analytics and decision tools, and has been an advisory board member of the London Technology Club since 2018. Ms. Felix holds a bachelor’s degree in chemical engineering and pre-med from the University of Pittsburgh.

Iron Mountain Board Chairperson, Pamela Arway, said: “Our Board of Directors is pleased to welcome Ms. Felix. Our Board will gain additional strength and expertise from her experience in the financial services, fintech and technology sectors.”

William L. Meaney, Iron Mountain President and CEO, said: “Having led complex global organizations through successful transformations in the U.S., Europe and Asia, Ms. Felix will bring valuable insights and perspectives to Iron Mountain as our company continues to grow.”

About Iron Mountain

Iron Mountain Incorporated (NYSE: IRM) is trusted by more than 240,000 customers in 60 countries, including approximately 95% of the Fortune 1000, to help unlock value and intelligence from their assets through services that transcend the physical and digital worlds. Our broad range of solutions address their information management, digital transformation, information security, data center and asset lifecycle management needs. Our longstanding commitment to safety, security, sustainability and innovation in support of our customers underpins everything we do.

To learn more about Iron Mountain, please visit www.IronMountain.com.

Investor Relations:

Mark Rupe

SVP, Head of Investor Relations

[email protected]

Erika Crabtree

Manager, Investor Relations

[email protected]

Press Enquiries:[email protected]

KEYWORDS: New Hampshire United States North America

INDUSTRY KEYWORDS: Networks Security Hardware Technology Software

MEDIA:

Logo
Logo
Photo
Photo
June Yee Felix (Photo: Business Wire)
Posted on

Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

First Breakthrough Therapy Designation for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan

Based on TROPION-Lung05 Phase II trial and supported by data from TROPION-Lung01 Phase III trial

WILMINGTON, Del.–(BUSINESS WIRE)–
Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with disease progression on or after treatment with an EGFR-tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.

The US Food and Drug Administration (FDA) BTD is designed to accelerate the development and regulatory review of potential new medicines that are intended to treat serious conditions and address significant unmet medical needs. The medicine needs to have shown encouraging preliminary clinical results that demonstrate substantial improvement on a clinically significant endpoint over available medicines.

The FDA granted this BTD based on data from the TROPION-Lung05 Phase II trial with supporting data from the TROPION-Lung01 Phase III trial. Results from a pooled analysis of patients with previously treated EGFRm NSCLC in these studies were presented this month at the European Society of Medical Oncology (ESMO) Asia 2024 Congress. This is the first BTD for datopotamab deruxtecan.

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “This Breakthrough Therapy Designation reinforces datopotamab deruxtecan as a promising potential therapy for patients with EGFR-mutated lung cancer who continue to face significant unmet needs following disease progression on or after initial treatments. We are proud to have long supported patients with EGFR-mutated lung cancer and look forward to the possibility of bringing another innovative treatment option to this community.”

Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo, said: “The Breakthrough Therapy Designation granted by the FDA underscores the significant unmet need for new treatments for patients with previously treated EGFR-mutated non-small cell lung cancer who have experienced disease progression. Datopotamab deruxtecan has the potential to play an important role in improving outcomes and we look forward to working closely with the FDA to bring this medicine to patients as quickly as possible.”

Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by AstraZeneca and Daiichi Sankyo.

AstraZeneca and Daiichi Sankyo recently announced the submission of a new Biologics License Application for accelerated approval in the US for datopotamab deruxtecan for the treatment of adult patients with locally advanced or metastatic EGFRm NSCLC who have received prior systemic therapies, including an EGFR-directed therapy.

Notes

Advanced non-small cell lung cancer

Nearly 2.5 million lung cancer cases were diagnosed globally in 2022.1 Lung cancer is broadly split into small or non-small cell lung cancer, the latter accounting for about 80% of cases.2 Approximately 10 to 15% of patients with NSCLC in the US and Europe, and 30 to 40% of patients in Asia have an EGFR mutation.3,4 The majority of EGFR mutations occur in tumors of nonsquamous histology.5

For patients with tumors that have an EGFR mutation, the established 1st-line treatment in the metastatic setting is an EGFR-TKI.6 While EGFR-TKIs have improved outcomes in the 1st-line setting, most patients eventually experience disease progression and receive subsequent therapies, such as chemotherapy.7-10

TROP2 is a protein broadly expressed in the majority of NSCLC tumors.11 There is currently no TROP2-directed ADC approved for the treatment of lung cancer.6,12

TROPION-Lung05

TROPION-Lung05 is a global, multicenter, single-arm, open-label Phase II trial evaluating the efficacy and safety of datopotamab deruxtecan in patients with locally advanced or metastatic NSCLC with actionable genomic alterations who have progressed on at least one TKI (with or without other systemic therapies) and on or after one regimen of platinum-based chemotherapy. Patients receiving up to four prior lines of treatment with tumors with one or more genomic alterations including EGFR, ALK, ROS1, NTRK, BRAF, RET or MET were eligible for the trial.

The primary trial endpoint is objective response rate (ORR) as assessed by blinded independent central review (BICR). Secondary efficacy endpoints include duration of response (DoR), disease control rate (DCR), clinical benefit rate, progression-free survival (PFS), time to response (TTR), overall survival (OS) and safety.

TROPION-Lung05 enrolled 137 patients globally in Asia, Europe and North America. For more information visit ClinicalTrials.gov.

TROPION-Lung01

TROPION-Lung01 is a global, randomized, multicenter, open-label Phase III trial evaluating the efficacy and safety of datopotamab deruxtecan versus docetaxel in adult patients with locally advanced or metastatic NSCLC with and without actionable genomic alterations who require systemic therapy following prior treatment. Patients with actionable genomic alterations were previously treated with an approved targeted therapy and platinum-based chemotherapy. Patients without known actionable genomic alterations were previously treated, concurrently or sequentially, with platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor.

The dual primary endpoints of TROPION-Lung01 are PFS as assessed by BICR and OS. Key secondary endpoints include investigator-assessed PFS, ORR, DoR, TTR, and DCR as assessed by both BICR and investigator, and safety.

TROPION-Lung01 enrolled approximately 600 patients in Asia, Europe, North America, Oceania and South America. For more information visit ClinicalTrials.gov.

Primary PFS results and interim OS results from TROPION-Lung01 were presented at the ESMO 2023 Congress. Final OS results were presented at IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer and simultaneously published in the Journal of Clinical Oncology in September 2024.

Datopotamab deruxtecan (Dato-DXd)

Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, datopotamab deruxtecan is one of six DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.

A comprehensive global clinical development program is underway with more than 20 trials evaluating the efficacy and safety of datopotamab deruxtecan across multiple cancers, including NSCLC, triple-negative breast cancer and HR-positive, HER2-low or negative breast cancer. The program includes seven Phase III trials in lung cancer and five Phase III trials in breast cancer evaluating datopotamab deruxtecan as a monotherapy and in combination with other anticancer treatments in various settings.

Daiichi Sankyo collaboration

AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialize fam-trastuzumab deruxtecan-nxki in March 2019 and datopotamab deruxtecan in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is responsible for the manufacturing and supply of fam-trastuzumab deruxtecan-nxki and datopotamab deruxtecan.

AstraZeneca in lung cancer

​AstraZeneca is working to bring patients with lung cancer closer to cure through the detection and treatment of early-stage disease, while also pushing the boundaries of science to improve outcomes in the resistant and advanced settings. By defining new therapeutic targets and investigating innovative approaches, the Company aims to match medicines to the patients who can benefit most.

The Company’s comprehensive portfolio includes leading lung cancer medicines and the next wave of innovations, including osimertinib and gefitinib; durvalumab and tremelimumab; fam-trastuzumab deruxtecan-nxki and datopotamab deruxtecan in collaboration with Daiichi Sankyo; savolitinib in collaboration with HUTCHMED; as well as a pipeline of potential new medicines and combinations across diverse mechanisms of action.

AstraZeneca is a founding member of the Lung Ambition Alliance, a global coalition working to accelerate innovation and deliver meaningful improvements for people with lung cancer, including and beyond treatment.

AstraZeneca in oncology

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 125 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on social media @AstraZeneca.

References

  1. World Health Organization. Global Cancer Observatory: Lung. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf. Accessed December 2024.

  2. American Cancer Society. Key Statistics for Lung Cancer. Available at: https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html#:~:text=NSCLC%20is%20the%20most%20common,be%20diagnosed%20with%20lung%20cancer. Accessed December 2024.

  3. Szumera-Ciećkiewicz A, et al. EGFR Mutation Testing on Cytological and Historical Samples in Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence. Int J Clin Exp Pathol. 2013;6(12): 2800-2812.

  4. Ellison G, et al. EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. J Clin Pathol. 2013;66(2):79-89.

  5. Prabhakar C. Translational Lung Cancer Research.2015; 4(2), 110-118.

  6. American Cancer Society. Targeted Drug Therapy for Non-Small Cell Lung Cancer. Available at: https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/targeted-therapies.html. Accessed December 2024.

  7. Chen R, et al. Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol. 2020:13(1):58.

  8. Majeed U, et al. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021;14(1):108.

  9. Morgillo F, et al. ESMO Open. 2016;1:e000060. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC5070275/. Accessed December 2024.

  10. Han B, et al. Onco Targets Ther. 2018;11:2121-9. Available at: https://www.dovepress.com/efficacy-of-pemetrexed-based-regimens-in-advanced-non-small-cell-lung–peer-reviewed-fulltext-article-OTT. Accessed December 2024.

  11. Mito R, et al. Clinical impact of TROP2 in non-small cell lung cancers and its correlation with abnormal p53 nuclear accumulation. Pathol Int. 2020;70(5):287-294.

  12. Rodríguez-Abreau D, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Onc. 2021 Jul;32(7): 881-895.

US-96427 Last Updated 12/24

Media Inquiries

Brendan McEvoy +1 302 885 2677

Chelsea Tressler +1 302 885 2677

US Media Mailbox: [email protected]

KEYWORDS: Delaware United States North America

INDUSTRY KEYWORDS: Oncology FDA Health Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

Lattice Semiconductor Announces Additional $100 Million Stock Repurchase Program Authorization

Lattice Semiconductor Announces Additional $100 Million Stock Repurchase Program Authorization

HILLSBORO, Ore.–(BUSINESS WIRE)–
Lattice Semiconductor Corporation (Nasdaq: LSCC), the low power programmable leader, today announced that its Board of Directors authorized the Company to repurchase up to an additional $100 million of its outstanding common stock through the end of December 2025. The Company has repurchased approximately 6 million shares since the fourth quarter of 2020 thereby reducing dilution by 4.3%.

Tonya Stevens, Interim Chief Financial Officer, said, “Our 2025 share repurchase program reflects our confidence in Lattice’s financial performance and continued strong cash flow. We remain committed to returning capital to shareholders while continuing to invest in the strategic initiatives that drive future growth, as we work to maximize long-term shareholder value.”

The 2025 repurchase program is effective immediately. Under the program, Lattice may purchase shares of its common stock through open market and privately negotiated transactions at prices deemed appropriate by management. The timing and amount of repurchase transactions under this program will depend on market conditions, share price, corporate and regulatory considerations, and other factors. The Company intends to conduct the program in compliance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended. The repurchase program may be suspended or discontinued by the Company at any time without prior notice.

Forward-Looking Statements Notice:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve estimates, assumptions, risks and uncertainties. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are neither historical facts nor assurances of future performance and may be forward-looking. Such forward-looking statements include, but are not limited to, statements relating to the amount of our outstanding capital stock we plan to or will purchase under the repurchase program and the timing and methods to execute such repurchases, the financial strength of the Company’s business, our strong cash flow, future growth, and the Company’s ability to deliver long-term value to stockholders. Other forward-looking statements may be indicated by words such as “will,” “could,” “should,” “would,” “may,” “expect,” “plan,” “project,” “anticipate,” “intend,” “forecast,” “future,” “believe,” “estimate,” “predict,” “propose,” “potential,” “continue” or the negative of these terms or other comparable terminology.

Actual results may differ materially from our expectations and are subject to risks and uncertainties that relate more broadly to our overall business, including those described in our filings with the Securities and Exchange Commission, including Lattice’s most recent Annual Report on Form 10-K, especially those under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, all of which are expressly incorporated herein by reference.

About Lattice Semiconductor Corporation:

Lattice Semiconductor (Nasdaq: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing communications, computing, industrial, automotive and consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.

For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, X, Facebook, YouTube, WeChat, or Weibo.

MEDIA:

Sophia Hong

Lattice Semiconductor Corporation

503-268-8786

[email protected]

INVESTORS:

Rick Muscha

Lattice Semiconductor Corporation

408-826-6000

[email protected]

KEYWORDS: Oregon United States North America

INDUSTRY KEYWORDS: Software Technology Networks Semiconductor

MEDIA:

Logo
Logo
Posted on

Newpark Resources Announces New Brand Identity, Aligning Strategic Focus on Specialty Rental Solutions for the Global Worksite Access Market

Newpark Resources Announces New Brand Identity, Aligning Strategic Focus on Specialty Rental Solutions for the Global Worksite Access Market

Newpark Resources rebrands to NPK International

NPK International to commence trading on the NYSE under the ticker symbol NPKI beginning December 19, 2024

THE WOODLANDS, Texas–(BUSINESS WIRE)–
Newpark Resources, Inc. (NYSE: NR) (“Newpark” or the “Company”) today announced that it has formally changed the Company name to NPK International Inc. (“NPK”), effective today.

Key highlights of the rebranding campaign include the following:

  • New brand identity. NPK is a leading worksite access solutions company committed to providing best-in-class products and services to support our customers critical infrastructure projects. Building on a legacy of innovation, NPK provides sustainable technologies that deliver superior quality and reliability to a diverse, growing base of domestic and international customers. NPK’s branding demonstrates a long-term commitment to delivering value-creating solutions that position its customers for long-term success.
  • New corporate website. In conjunction with its rebranding, the Company has launched a new corporate website, consistent with its new brand identity. The new website, which may be accessed at www.npki.com, highlights NPK’s strategic focus, breadth of capabilities, and commitment to delivering access solutions that drive sustainable, efficient project support across various industries.
  • New ticker symbol. The Company’s common stock will begin trading on NYSE under the ticker symbol ‘NPKI’ prior to market open on December 19, 2024. This will replace the Company’s current ticker symbol ‘NR’.

“Today, we enter an exciting new chapter in the history of our company with the formal launch of NPK International, an organization committed to serving the diverse, high-performance requirements of the global worksite access market,” stated Matthew Lanigan, President and Chief Executive Officer of NPK.

“NPK is a vertically integrated, pure-play provider of worksite access solutions serving an established base of global infrastructure customers, including those in the utility and energy markets,” stated Lanigan. “As NPK, we will continue to prioritize a disciplined, return-driven approach toward capital allocation as we seek to maximize shareholder value, while providing our customers with a superior solutions offering that emphasizes durability, cost-efficiency, compliance, and sustainability. We have a well-defined strategic roadmap for profitable growth and look forward to having our shareholders, customers, and partners join us as we continue to build and strengthen our industry-leading worksite access brand.”

ABOUT NPK INTERNATIONAL

NPK International Inc. is a site access solutions company that manufactures, sells, and rents industry-leading sustainable composite matting products, along with a full suite of services, including planning, logistics, and remediation. As a geographically diversified company, the Company delivers superior quality and reliability across critical infrastructure markets, including electrical transmission & distribution, oil and gas exploration, pipeline, renewable energy, petrochemical, construction, and other industries. For more information, visit our website at www.npki.com.

IR CONTACT

Noel Ryan or Paul Bartolai

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Construction & Property Engineering Chemicals/Plastics Utilities Oil/Gas Manufacturing Alternative Energy Energy Other Construction & Property

MEDIA:

Logo
Logo
Posted on

ICE Expands Global Energy Offering with the Launch of Japanese Power Futures

ICE Expands Global Energy Offering with the Launch of Japanese Power Futures

JAPAN & LONDON & NEW YORK & AMSTERDAM–(BUSINESS WIRE)–
Intercontinental Exchange, Inc. (NYSE:ICE), a leading global provider of technology and data, today announced the latest addition to its global energy offering with the launch of Japanese Power Futures.

ICE has launched four Japanese Power Financial Baseload and Peakload Futures covering the Tokyo and Kansai areas respectively, allowing market participants to manage exposure to the day-ahead auction price of the Japanese Electric Power Exchange (JEPX) for these areas.

“By offering Japanese Power Futures on a single platform alongside our natural gas, coal, oil, clean energy attributes and carbon contracts, ICE is providing customers with a critical edge in navigating energy markets,” said Gordon Bennett, Managing Director of Utility Markets at ICE. “Secondary fuels including electricity are produced through the conversion of primary energy sources like natural gas, coal and oil, and the price of electricity is derived from the interaction of these competing input fuels, all of which trade on ICE. Natural gas and coal make up the majority of Japan’s electricity generation and through trading of these contracts on ICE, customers benefit from improved price dissemination.”

ICE’s Japanese Power Financial Futures will be offered in monthly, quarterly and seasonal contracts as well as a Calendar and Fiscal Year contract. In addition, customers can trade spreads between Tokyo and Kansai to manage positions and price differences across these regions, as well as manage exposure to regional price risks.

ICE’s global energy markets are the most liquid in the world to trade energy derivatives. Japanese Power futures will join ICE’s global energy offering which includes the benchmark price for natural gas in North-East Asia JKM LNG (Platts), the global benchmark TTF, the U.S. benchmark Henry Hub and globalCOAL Newcastle Coal Futures, as well as ICE’s complex of over 800 oil and refined products including ICE Brent. Open interest across ICE’s energy markets is up 20% year-over-year.

For more information, email [email protected].

About Intercontinental Exchange

Intercontinental Exchange, Inc. (NYSE: ICE) is a Fortune 500 company that designs, builds and operates digital networks that connect people to opportunity. We provide financial technology and data services across major asset classes helping our customers access mission-critical workflow tools that increase transparency and efficiency. ICE’s futures, equity, and options exchanges – including the New York Stock Exchange – and clearing houses help people invest, raise capital and manage risk. We offer some of the world’s largest markets to trade and clear energy and environmental products. Our fixed income, data services and execution capabilities provide information, analytics and platforms that help our customers streamline processes and capitalize on opportunities. At ICE Mortgage Technology, we are transforming U.S. housing finance, from initial consumer engagement through loan production, closing, registration and the long-term servicing relationship. Together, ICE transforms, streamlines and automates industries to connect our customers to opportunity.

Trademarks of ICE and/or its affiliates include Intercontinental Exchange, ICE, ICE block design, NYSE and New York Stock Exchange. Information regarding additional trademarks and intellectual property rights of Intercontinental Exchange, Inc. and/or its affiliates is located here. Key Information Documents for certain products covered by the EU Packaged Retail and Insurance-based Investment Products Regulation can be accessed on the relevant exchange website under the heading “Key Information Documents (KIDS).”

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 – Statements in this press release regarding ICE’s business that are not historical facts are “forward-looking statements” that involve risks and uncertainties. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ICE’s Securities and Exchange Commission (SEC) filings, including, but not limited to, the risk factors in ICE’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on February 8, 2024.

Category: EXCHANGES

ICE-CORP

Source: Intercontinental Exchange

ICE Media:

Jess Tatham

[email protected]

+44 7377 947136

ICE Investor:

Katia Gonzalez

[email protected]

(678) 981-3882

KEYWORDS: New York United States United Kingdom Japan North America Asia Pacific Europe Netherlands

INDUSTRY KEYWORDS: Finance Banking Energy Professional Services Other Energy

MEDIA:

Logo
Logo
Posted on

Air Industries Group Secures $11 Million Contract for Landing Gear Assemblies for the US Navy E-2D Advanced Hawkeye Aircraft

Air Industries Group Secures $11 Million Contract for Landing Gear Assemblies for the US Navy E-2D Advanced Hawkeye Aircraft

BAY SHORE, N.Y.–(BUSINESS WIRE)–Air Industries Group (“Air Industries”) (NYSE American: AIRI), a leading manufacturer of precision components and assemblies for large aerospace and defense prime contractors, today announced that it has secured a follow-on contract valued at over $11.0 million for landing gear assemblies for the U.S. Navy E-2D Advanced Hawkeye aircraft. Air Industries has been a key supplier to the E-2 family of aircraft for decades, underscoring its long-standing role in supporting critical defense programs.

Production is scheduled to commence in the second half of 2025, upon the arrival of raw materials, with delivery of finished product set to begin in the first quarter of 2026.

Lou Melluzzo, Chief Executive Officer of Air Industries Group remarked: “The E-2D Advanced Hawkeye is a mission-critical platform for the US Navy, managing the airspace surrounding a Carrier Battle Group by identifying threats and coordinating aircraft movements. This contract grew in size during negotiations, reflecting the ongoing importance of the aircraft not only to the Navy but also to an expanding number of foreign military customers.”

Melluzzo continued: “The E-2D has been a cornerstone of Air Industries’ operations for many years. This follow-on contract reaffirms our customer’s trust in our capabilities, reliability, and performance. We are proud to continue supporting this vital program for both domestic and international defense needs.”

ABOUT AIR INDUSTRIES GROUP

Air Industries Group is a leading manufacturer of precision components and assemblies for large aerospace and defense prime contractors. Its products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. Whether it is a small individual component or complete assembly, its high quality and extremely reliable products are used in mission critical operations that are essential for the safety of military personnel and civilians.

FORWARD LOOKING STATEMENTS

Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, earnings and Adjusted EBITDA, the ability to realize firm backlog and projected backlog, cost cutting measures, potential future results and acquisitions, are examples of such forward-looking statements. The forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of projects due to variability in size, scope and duration, the inherent discrepancy in actual results from estimates, projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

NON-GAAP FINANCIAL MEASURES

The Company uses Adjusted EBITDA, a Non-GAAP financial measure as defined by the SEC, as a supplemental profitability measure because management finds it useful to understand and evaluate results, excluding the impact of non-cash depreciation and amortization charges, stock based compensation expenses, and nonrecurring expenses and outlays, prior to consideration of the impact of other potential sources and uses of cash, such as working capital items. This calculation may differ in method of calculation from similarly titled measures used by other companies and may be different than the EBITDA calculation used by our lenders for purposes of determining compliance with our financial covenants. This Non-GAAP measure may have limitations when understanding performance as it excludes the financial impact of transactions such as interest expense necessary to conduct the Company’s business and therefore are not intended to be an alternative to financial measure prepared in accordance with GAAP. The Company has not quantitatively reconciled its forward looking Adjusted EBITDA target to the most directly comparable GAAP measure because items such as amortization of stock-based compensation and interest expense, which are specific items that impact these measures, have not yet occurred, are out of the Company’s control, or cannot be predicted. For example, quantification of stock-based compensation is not possible as it requires inputs such as future grants and stock prices which are not currently ascertainable.

Anyone wishing to contact us or send a message can also do so by visiting: www.airindustriesgroup.com/contact-us/

Air Industries Group

Chief Financial Officer

631-328-7039

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Steel Contracts Air Engineering Transport Military Aerospace Manufacturing Defense

MEDIA:

Logo
Logo
Posted on

U.S. Special Operations Command Expands Contract with Palantir to Deliver Advanced AI and Mission Manager Capabilities

U.S. Special Operations Command Expands Contract with Palantir to Deliver Advanced AI and Mission Manager Capabilities

DENVER–(BUSINESS WIRE)–
Palantir Technologies Inc. (NASDAQ: PLTR) today announced an expansion of its contract with the U.S. Special Operations Command (USSOCOM) to deliver technology solutions in support of enterprise capabilities. The one-year delivery is valued at $36.8 million and establishes Palantir as the lead software integrator for USSOCOM’s Mission Command System (MCS) while expanding the technology solutions supporting U.S. Special Operations Forces (SOF) globally.

This contract award leverages Palantir’s multi-vendor development ecosystem and the Ontology Software Development Kit (OSDK) to expedite software deployment at the edge. The expanded partnership also enables pilot projects across the broader Command, inclusive of efforts dedicated to bringing Palantir’s cutting-edge artificial intelligence (AI) capabilities to USSOCOM.

“USSOCOM continues to be at the forefront of adopting emergent technology and we are looking forward to this new stage of our long-time partnership,” said Akash Jain, President, Palantir USG. “Palantir’s Mission Manager is positioned to innovate the Defense industry by providing software to enable and operationalize commercial capabilities for U.S. Government missions. USSOCOM understands that commercial software can be the differentiator in the battlespace and we are steadfast in our commitment to supporting USSOCOM forces around the world.”

This contract award marks the first deployment of Palantir’s Mission Manager to SOF Units. Mission Manager employs Palantir’s secure, Kubernetes-based infrastructure to streamline the Government’s onboarding of innovative and emergent technologies from commercial software vendors into a secure environment. Government administrators have full visibility for operational readiness, risk assessment, and informed decision-making, whether in a connected, disconnected, cloud, or edge environment. This ultimately enables the end user to leverage third-party applications and functionalities within the larger Palantir ecosystem, enabling a more expansive set of capabilities that meet Palantir’s – and the Government’s – strict security parameters.

This contract is the result of the trust built over more than a decade of collaboration between our communities and is a reaffirmation of Palantir’s long-standing commitment to delivering the most capable and reliable software solutions for the Warfighter.

About Palantir Technologies Inc.

Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir’s expectations regarding the amount and the terms of the contract and the expected benefits of our software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include our ability to meet the unique needs of our customer; the failure of our platforms to satisfy our customer or perform as desired; the frequency or severity of any software and implementation errors; our platforms’ reliability; and our customer’s ability to modify or terminate the contract. Additional information regarding these and other risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

Media Contact

Morgan Gress

[email protected]

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Technology Contracts Military Professional Services Software Government Technology Data Analytics Artificial Intelligence Defense

MEDIA:

Logo
Logo
Posted on

Devon Energy President and CEO, Rick Muncrief, to Retire March 1, 2025; Clay Gaspar, Devon Chief Operating Officer, to Succeed Muncrief

OKLAHOMA CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) — Rick Muncrief, 66, has announced his retirement from the position of President and Chief Executive Officer and member of the Board of Directors of Devon Energy Corporation (NYSE: DVN), effective March 1, 2025. The board of directors has appointed Clay Gaspar, currently Devon’s Chief Operating Officer, to succeed Muncrief as President and CEO and as a member of the board, effective March 1, 2025.

“Rick’s vision and stewardship have delivered significant value to Devon shareholders since the merger with WPX Energy in 2021,” said John Bethancourt, Devon’s board chair. “Rick’s contributions to the oil and gas business go well beyond Devon. He is a 45-year veteran and recognized leader in our industry successfully serving multiple companies in technical and management roles. He has also held leadership positions in numerous industry trade groups and civic organizations. On behalf of Devon’s employees and the board of directors, I would like to thank Rick for his service to Devon and our industry throughout his long-distinguished career.”

“Clay’s selection as our next CEO is the result of a comprehensive succession planning process conducted by our board,” said Bethancourt. “He is an experienced leader, with the vision and industry expertise to guide Devon as we move forward. We are excited to collaborate with Clay to build upon the past success of Devon and create additional long-term value for our shareholders.”

“It has been an honor to lead Devon over the last four years and WPX Energy for the seven years prior as well. I believe the company is nicely positioned for the future. Our portfolio of assets is second to none and I am confident our experienced leadership team and talented employees will take the company to greater heights in the future,” said Muncrief. “Clay is a proven leader with significant experience in all aspects of our business and I couldn’t be more excited about Devon’s future with him in the CEO role.”

Gaspar said, “I am excited and humbled for the opportunity to lead such an outstanding organization. I want to thank Rick for his leadership and mentorship. We will remain focused on operating excellence across our portfolio of assets to deliver competitive and sustainable returns for our shareholders. Devon’s strategic objectives will remain the same while we leverage this opportunity to raise the bar.” 

Devon Energy Corporation is an Oklahoma City-based independent energy company engaged in oil and gas exploration and production. Devon is a leading U.S.-based independent oil and gas producer and is included in the S&P 500 Index. For additional information, visit our website at www.devonenergy.com.

Investor Contacts

Rosy Zuklic, 405-552-7802
Chris Carr, 405-228-2496

Media Contact

Michelle Hindmarch, 405-552-7460

This press release was published by a CLEAR® Verified individual.



Posted on

Dollar General Releases Holiday Deals for December 9-14 As Part of DG’s 24 Days of Savings

Dollar General Releases Holiday Deals for December 9-14 As Part of DG’s 24 Days of Savings

GOODLETTSVILLE, Tenn.–(BUSINESS WIRE)–
Dollar General (NYSE: DG) announced its holiday daily discounted items for December 9-14 as part of its 24 Days of Savings. The retailer is featuring one deal each day from Sunday, December 1st and running through Christmas Eve.

Current and upcoming deals include:

  • Monday, December 9th – $4 Holiday Slippers (reg $8)
  • Tuesday, December 10th – 2 for $4 Pillsbury Grands!™ Flaky Layer Buttermilk Biscuits 16.3 oz, Pillsbury™ Crescent Rolls 8 oz., or Pillsbury™ Cinnamon Rolls 12.4 oz. (must buy 2)
  • Wednesday, December 11th – $15 Jumbo Plush Bear, Dino or Unicorn (reg $30)
  • Thursday, December 12th – $2 True Living™ Plastic Cups 18 oz. / 50 ct. (reg $4)
  • Friday, December 13th– $1 Holiday Style Wrapping Paper (reg $3)
  • Saturday, December 14th – $8 Pre-Lit 4 ft Holiday Tree (reg $20)

The 24 Days of Savings offers will be in addition to the current Decked Out in Deals holiday savings at Dollar General including DG Deal Days with discounts, promotions and instant savings on more than 6,000 items storewide. Featured daily deals for the upcoming week will be announced on Sunday morning in the DG app, on Dollar General’s social media, on the DG.com 24 Days of Savings landing page, and on in-store signage.

Customers can shop the 24 Days of Savings at any of DG’s more than 20,000 stores nationwide. 24 Days of Savings items are while supplies last and not available on-line.

About Dollar General Corporation

Dollar General Corporation (NYSE: DG) is proud to serve as America’s neighborhood general store. Founded in 1939, Dollar General lives its mission of Serving Others every day by providing access to affordable products and services for its customers, career opportunities for its employees, and literacy and education support for its hometown communities. As of November 1, 2024, the Company’s 20,523 Dollar General, DG Market, DGX and pOpshelf stores across the United States and Mi Súper Dollar General stores in Mexico provide everyday essentials including food, health and wellness products, cleaning and laundry supplies, self-care and beauty items, and seasonal décor from our high-quality private brands alongside many of the world’s most trusted brands such as Coca Cola, PepsiCo/Frito-Lay, General Mills, Hershey, J.M. Smucker, Kraft, Mars, Nestlé, Procter & Gamble and Unilever.

Media Hotline: 1-877-944-DGPR (3477)

[email protected]

KEYWORDS: Tennessee United States North America

INDUSTRY KEYWORDS: Discount/Variety Toys Supermarket Specialty Home Goods Convenience Store Food/Beverage Cosmetics Retail

MEDIA:

Logo
Logo